arrow
E

Emmanuel Bachy

lyon sud hospital center
H指数:48
被引数:1.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

End-of-induction circulating tumor DNA outperforms conventional cellular MRD for predicting early progression in follicular lymphoma: an ancillary study of the RELEVANCE randomized trial

诱导治疗结束时的循环肿瘤DNA优于常规细胞微小残留病,用于预测滤泡性淋巴瘤的早期进展:RELEVANCE随机试验的辅助研究

2026-09-290
OAAI
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis

二线阿西美单抗 ciloleucel 在不适合移植的大B细胞淋巴瘤中的最终分析

2026-09-230
OAAI
Response kinetics following CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry

大B细胞淋巴瘤CAR T细胞疗法后的应答动力学:DESCAR-T登记研究中的LYSA研究

2026-08-210
PRE
Single-cell genomics highlight MYC-associated metabolic activation and altered cell interactions in T-prolymphocytic leukemia progression

单细胞基因组学揭示了MYC相关的代谢激活以及在T原淋巴细胞白血病进展中改变的细胞相互作用

2026-03-090
OAAI
Health-related quality of life after second-line Axi-cel in transplant-ineligible patients with large B-cell lymphoma
2026-01-130
OAAI
Early time-to-relapse as a survival prognosticator in mature T-cell/NK-cell lymphomas: results from the PETAL Consortium

早期复发时间作为成熟T细胞/NK细胞淋巴瘤的生存预后指标:PETAL Consortium的研究结果

Blood
IF23.1
2025-12-080
OAAI
Correction: Divergent molecular pathways drive monomorphic epitheliotropic and enteropathy-associated intestinal T-cell lymphoma

更正:不同的分子通路驱动单形态上皮表型肠道T细胞淋巴瘤和肠病相关肠道T细胞淋巴瘤。

Leukemia
IF13.4
2025-11-200
OAAI
Late failure of aggressive B-cell lymphoma following CAR T-cell therapy: a LYSA study from the DESCAR-T registry

CAR T细胞疗法后侵袭性B细胞淋巴瘤的晚期复发:一项来自DESCAR-T登记研究的LYSA研究

2025-10-240
OAAI
Invasive Fungal Infections after CD19 CAR T-cell Therapy for B-Cell Lymphoma: a LYSA study from the DESCAR-T Registry

CD19 CAR T细胞疗法治疗B细胞淋巴瘤后的侵袭性真菌感染:一项来自DESCAR-T登记研究的LYSA研究

2025-10-160
OAAI
Divergent molecular pathways drive monomorphic epitheliotropic and enteropathy-associated intestinal T-cell lymphoma

分歧的分子通路驱动单形态上皮亲嗜性及肠病相关肠道T细胞淋巴瘤

Leukemia
IF13.4
2025-10-070
OA
Brentuximab Vedotin addition to Gemcitabine in Relapsed or Refractory Peripheral T-cell Lymphoma: a LYSA Phase II Study

Brentuximab Vedotin联合Gemcitabine治疗复发或难治性外周T细胞淋巴瘤:一项LYSA II期研究

2025-08-060
OAAI
Health-Related Quality of Life With Odronextamab Monotherapy for Relapsed/Refractory Follicular Lymphoma in the ELM-2 Study

奥德诺克单抗单药治疗复发/难治性滤泡性淋巴瘤的EML-2研究中的健康相关生活质量

2025-05-230
OAAI
TRANSCAR: real-world outcomes of CD19 CAR T-cell therapy in relapsed/refractory transformed indolent lymphomas

TRANSCAR:CD19 CAR T细胞疗法在复发/难治性转化型惰性淋巴瘤中的真实世界疗效

2025-05-050
OAAI
Atezolizumab, obinutuzumab and venetoclax for the treatment of patients with relapsed/refractory B non-Hodgkin lymphoma: Final analysis of a phase II trial from the LYSA group

阿特珠单抗、奥比妥珠单抗和维奈托克用于治疗复发/难治性B非霍奇金淋巴瘤患者: LYSA组II期试验的最终分析

2025-04-260
OAAI
Myeloid neoplasms after CD19-directed CAR T cells therapy in long-term B-cell lymphoma responders, a rising risk over time?

长期B细胞淋巴瘤应答者接受CD19定向CAR T细胞治疗后出现的髓系肿瘤,风险是否随时间推移而增加?

LEUKEMIA
IF13.4
2025-04-240
OA
Efficacy of tazemetostat in combination with R-CHOP in elderly patients newly diagnosed with diffuse large B cell lymphoma: results of the EpiRCHOP phase II study of the LYSA

塔泽莫斯托stat与R-CHOP联合治疗新诊断弥漫性大B细胞淋巴瘤老年患者的疗效:LYSA的EpiRCHOP II期研究结果

2025-04-010
PRE
Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma treated with anti-CD19 CAR-T cells: CARTHYM, a study from the French national DESCAR-T registry

复发或难治性原发纵隔B细胞淋巴瘤患者接受抗CD19 CAR-T细胞治疗的结局:CARTHYM,一项来自法国国家DESCAR-T登记研究的报告

2025-02-182
OAAI